India Pharma Sector Ka Naya Game: Generics Ko Bye Bye, Biologics Pe Focus! Par Hurdles Hain Bahut Saare

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAnanya Iyer|Published at:
India Pharma Sector Ka Naya Game: Generics Ko Bye Bye, Biologics Pe Focus! Par Hurdles Hain Bahut Saare
Overview

India ki pharma industry ab generics se aage badhke high-value biologics aur biosimilars par focus kar rahi hai. Government bhi is shift ko support kar rahi hai, par is transition mein kaafi bade challenges aa rahe hain.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

India ka naya plan: Generics se Biologics ki taraf move!

Dekho, India ki pharma companies ab sirf generics pe depend nahi reh sakti. Kyunki generics mein price pressure aur competition bahut badh gaya hai, minister Anupriya Patel ne bhi bola hai ki future growth ke liye higher-value products zaruri hain. World market mein biologics ka craze hai aur ismein future hai.

Global players jaise US aur Europe toh bahut pehle se biologics mein invest kar rahe hain. Aur China bhi tezi se apni capacity badha raha hai, toh humein bhi abhi action lena padega.

Government ke Bade Plans: SHAKTI aur Naye Reforms

Is transition ko boost dene ke liye sarkar ne kuch zabardast plans banaye hain.

  • Biopharma SHAKTI: Is program ke through Rs 10,000 Crore ka investment kiya jayega next 5 saal mein. Isse domestic manufacturing aur R&D strong hogi.
  • CDSCO Reforms: Health ministry CDSCO (Central Drugs Standard Control Organisation) ko rebuild kar rahi hai. Lagbhag 1,500 experts hire kiye jayenge taaki drug approvals fast ho sakein aur scientific review better ho.
  • AI ka use: Drug discovery mein AI (Artificial Intelligence) ko integrate karne ka bhi plan hai, aur 1,000 clinical trial sites develop kiye jayenge.

Par, Sab Itna Aasan Nahi Hai!

Itne bade plans ke bawajud, India ka biologics leader banna ek mushkil race hai.

  • Funding ka issue: Jo Rs 10,000 Crore SHAKTI ke liye rakhe hain, woh global pharma giants ke R&D budgets ke saamne kam lag sakte hain.
  • Talent ki kami: 1,500 experts hire karna ek bada challenge hai. Specialized scientific talent ko attract aur retain karna easy nahi hoga.
  • Execution mein deri: India mein bade government initiatives mein pehle bhi implementation delays aur funding issues dekhe gaye hain.
  • High Risk R&D: Biologics develop karna ek bahut lamba aur risky process hai. Generics ke compare mein success rate kam hota hai. Iske liye sirf paisa nahi, balki scientific expertise, advanced research infrastructure aur regulatory pathways ki deep samajh chahiye.

Analysts ka kehna hai ki India mein potential toh hai, par is vision ko poora hone mein time lagega. Long-term commitment, achhe execution aur innovation par focus karna hoga.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.